A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients

  • Authors:
    • P. Correale
    • D. Cerretani
    • C. Remondo
    • I. Martellucci
    • S. Marsili
    • M. La Placa
    • A. Sciandivasci
    • L. Paolelli
    • A. Pascucci
    • M. Rossi
    • M. Di Bisceglie
    • G. Giorgi
    • G. Gotti
    • G. Francini
  • View Affiliations

  • Published online on: July 1, 2006     https://doi.org/10.3892/or.16.1.133
  • Pages: 133-140
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of this pilot phase II trial was to investigate the toxicity and anti-tumour activity of a novel metronomic regimen of weekly cisplatin (CDDP) and oral etoposide (VP16) in high-risk patients with advanced NSCLC. The study enrolled 31 high-risk patients (27 men and 4 women aged 16-82 years; mean, 64.3) with NSCLC (18 stage IIIB and 13 stage IV) and an ECOG performance status of ≤3, all of whom received weekly CDDP 30 mg/m2 iv on days 1, 8, 14 and 28 of each cycle and oral daily etoposide 50 mg/m2 on 21 of the 28 days. The most frequent adverse events were grade III leukopenia and anemia; nevertheless, three patients died of pulmonary embolism after 2, 3 and 6 weeks of treatment. The objective response (OR) rate was 45.2% (2 complete and 12 partial), and the disease control rate was 58.1% (14 ORs and 4 disease stabilisations). The mean time to progression and survival were respectively nine months (95% CI, 6.3-15.8 months) and thirteen months (95% CI, 9.1-20.5 months). Pharmacological analysis showed that this metronomic regimen allows a much greater median monthly area under the curve of CDDP and VP16 than conventional treatment schedules. Our findings also suggest that this treatment schedule may affect tumour growth and neoangiogenesis by changing peripheral blood vascular-endothelial growth factor levels. These preliminary results indicate that our metronomic regimen is well tolerated and active, even in patients with a very poor prognosis.

Related Articles

Journal Cover

July 2006
Volume 16 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Correale, P., Cerretani, D., Remondo, C., Martellucci, I., Marsili, S., La Placa, M. ... Francini, G. (2006). A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients. Oncology Reports, 16, 133-140. https://doi.org/10.3892/or.16.1.133
MLA
Correale, P., Cerretani, D., Remondo, C., Martellucci, I., Marsili, S., La Placa, M., Sciandivasci, A., Paolelli, L., Pascucci, A., Rossi, M., Di Bisceglie, M., Giorgi, G., Gotti, G., Francini, G."A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients". Oncology Reports 16.1 (2006): 133-140.
Chicago
Correale, P., Cerretani, D., Remondo, C., Martellucci, I., Marsili, S., La Placa, M., Sciandivasci, A., Paolelli, L., Pascucci, A., Rossi, M., Di Bisceglie, M., Giorgi, G., Gotti, G., Francini, G."A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients". Oncology Reports 16, no. 1 (2006): 133-140. https://doi.org/10.3892/or.16.1.133